Jones v. Glaxosmithkline LLC

CourtDistrict Court, District of Columbia
DecidedDecember 20, 2010
DocketCivil Action No. 2008-0566
StatusPublished

This text of Jones v. Glaxosmithkline LLC (Jones v. Glaxosmithkline LLC) is published on Counsel Stack Legal Research, covering District Court, District of Columbia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Jones v. Glaxosmithkline LLC, (D.D.C. 2010).

Opinion

UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA

) FLOYD JONES, ) ) Plaintiff, ) ) v. ) Civil Action No. 08-566 (RMC) ) GLAXOSMITHKLINE, LLC, ) ) Defendant. ) )

MEMORANDUM OPINION

Floyd Jones, an African-American man, sues GlaxoSmithKline, LLC (“GSK”), his

former employer, alleging harassment and hostile work environment based on his race and sex in

violation of Title VII of the Civil Rights Act of 1964, 42 U.S.C. §§ 2000e et seq., and wrongful

termination in breach of an implied contract.1 On March 1, 2010, at the end of prolonged discovery,

GSK filed a motion for summary judgment. After three extensions, Mr. Jones filed no opposition.

Therefore, on April 23, 2010, GSK moved the Court to treat its unopposed motion for summary

judgment as conceded, and the Court issued an order to show cause why said motion should not be

granted. Mr. Jones responded on April 26, 2010, and stated: “If Plaintiff does not file [his

opposition] on April 28, 2010, Plaintiff has no further extension or opposition to Defendant’s Motion

for Summary Judgment.” Pl.’s Opp’n to Def.’s Mot. to Treat its Unopposed Mot. as Conceded [Dkt.

# 49] ¶ 10. Nonetheless, Mr. Jones’s opposition was filed on April 29, 2010, with no motion for

1 See Third Am. Compl. [Dkt. #41] ¶ 1. Since filing the Third Amended Complaint, Mr. Jones has “concede[d] all counts except the claim of Harassment under Title VII and the claim of wrongful termination.” See Pl.’s Opp’n to Def.’s Mot. to Treat its Unopposed Mot. as Conceded [Dkt. # 49] ¶ 6; Pl.’s Opp’n to Def.’s Mot. for Summ. J. [Dkt. # 50] 3. leave to file late, and GSK followed with a reply on June 21, 2010. Given the history of this case,

the Court could take Mr. Jones at his word and grant summary judgment as conceded or dismiss the

matter for failure to prosecute. Nonetheless, given the “strong polic[y] favoring the resolution of

genuine disputes on their merits,” Jackson v. Beech, 636 F.2d 831, 835 (D.C. Cir. 1980), the Court

has reviewed the pleadings and decides the case on its merits. Summary judgment will be granted

to GSK.

I. FACTS

GSK hired Mr. Jones as a Pharmaceutical Consultant and he began work on

approximately June 26, 1995.2 In that role, he was principally responsible for calling on hospitals,

medical centers, and healthcare professionals to engage in face-to-face discussions regarding the use

and benefits of GSK’s medical products. In September 2003, Mr. Floyd assumed the position of

Oncology Senior Executive Account Manager, a position he held until his discharge on March 30,

2006. His basic duties continued to entail meeting with healthcare professionals to discuss and

promote GSK’s products.

A. Events Leading to Mr. Jones’s Discharge

GSK restructured its Oncology Division in January 2005 and Mr. Jones was assigned

to the Acute Care Group. That reassignment placed him under the supervision of Joanna Turbeville,

who was the Regional Sales Director. GSK measures the performance of its sales representatives,

in part, based upon their sales rankings, which GSK prepares on a quarterly basis. In the last quarter

of 2004, Mr. Jones was ranked in the top 15% in the nation among GSK’s salesforce. Starting in

2 The facts which bear no citation are from the Defendant’s Statement of Material Facts that Mr. Jones does not contest. See Def.’s Facts [Dkt. # 44]; see also Opp’n 5–10.

-2- January 2005, his sales rankings began to decline and, over the course of the next four quarters,

plummeted from the top 17%, top 52%, top 71%, top 82%, until the first quarter of 2006, when Mr.

Jones tied for last in the nation. As Mr. Jones notes, the precipitous drop in his sales performance

coincided with Ms. Turbeville’s assignment as his supervisor. See Opp’n [Dkt. # 50] 6 ¶ 18.

As his supervisor, Ms. Turbeville spent time in the field with Mr. Jones to observe

his work performance on five occasions: in March 2005, June 2005, November 2005, January 2006,

and March 2006. These “work contacts” are intended to give GSK supervisors an opportunity to

observe sales representatives as they call on health care professionals, after which the supervisor

provides feedback on the representative’s performance. The substance and feedback from these

work contacts were captured in written notes called “Field Coaching Tools,” which Ms. Turbeville

prepared and then shared with Mr. Jones. In the first of these Field Coaching Tools, which followed

the March 2005 work contact, Ms. Turbeville noted that “Floyd has the desire and skills to move this

product,” and that her expectation was that “Floyd will move a lot of business.” Def.’s Mem. in

Supp. of Mot. for Summ. J. [Dkt. # 44] (“Def.’s Mem.”), [Ex. 2] Decl. of Joanna Turbeville

(“Turbeville Decl.”), [Ex. A] Field Coaching Tool 3/23 & 3/24. Ms. Turbeville suggested: “Look

at your geography from an account basis and identify where your efforts will get the maximum ROI

[return on investment]. Find ways to see the orthos [orthopaedic doctors] that are driving your

business.” Id. Further, she suggested that he “[f]ocus cslls [sic] mostly on selling the product versus

sharing information.” Id. Despite these generally positive comments, Mr. Jones thought that Ms.

Turbeville was “very contentious” during this work contact and that she “challenge[d] me without

any resolutions to help me improve the situation.” Def.’s Mem., [Ex. 1] Decl. of Mary Kate Harkins,

[Ex. D] Floyd Jones GSK Employee Issues File (“Jones GSK Employee Issues File”) 1 (quoting

-3- Week of 3/21/05 entry).

When Ms. Turbeville next worked with Mr. Jones in June 2005, she expressed

concerns about his “market knowledge” and strategic analysis and planning. Turbeville Decl. ¶ 9;

see also id., [Ex. B] Field Coaching Tool (undated). Specifically, Ms. Turbeville observed that Mr.

Jones did not seem to have his routing — a schedule of doctors to call on — well developed. Id.,

[Ex. B] Field Coaching Tool (undated) ( “Floyd need[s] to get the routing done and spend more time

selling and less time tracking down the doctor.”). She was concerned that Mr. Jones spent so much

time finding doctors that it limited the amount of time he could spend actually selling the product.

See Turbeville Decl. ¶ 9. She found that he was “[g]ood at sharing the information, [but] need[ed]

to include the visual and clinical. Go over the clinical as you show it. You know the data but need

to sell it with a sense of urgency.” Id., [Ex. B] Field Coaching Tool (undated). Mr. Jones was also

approximately rated “fair” in the four of five “Winning Practices” ranking categories in which he

was rated. Mr. Jones was not rated in the category Teamwork & Leadership. Ms. Turbeville noted

that she was “[s]till determining this.” Id. In response, Mr. Jones wrote:

I have been dis-empowered and discouraged by the clash of personalities that have existed on this team over the past several months.3 The routing of physicians requires me to spend a good portion of my time providing information to the nurses and the Doctor in the hospital, and I have good access in some areas and adequate access in others.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Meritor Savings Bank, FSB v. Vinson
477 U.S. 57 (Supreme Court, 1986)
Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
Harris v. Forklift Systems, Inc.
510 U.S. 17 (Supreme Court, 1993)
Oncale v. Sundowner Offshore Services, Inc.
523 U.S. 75 (Supreme Court, 1998)
Faragher v. City of Boca Raton
524 U.S. 775 (Supreme Court, 1998)
National Railroad Passenger Corporation v. Morgan
536 U.S. 101 (Supreme Court, 2002)
Federal Deposit Insurance v. Bender
127 F.3d 58 (D.C. Circuit, 1997)
Stewart, Sonya v. Evans, Donald L.
275 F.3d 1126 (D.C. Circuit, 2002)
Burke, Kenneth M. v. Gould, William B.
286 F.3d 513 (D.C. Circuit, 2002)
Roebuck, Linda v. Washington, Odie
408 F.3d 790 (D.C. Circuit, 2005)
George, Diane v. Leavitt, Michael
407 F.3d 405 (D.C. Circuit, 2005)
Brady v. Office of the Sergeant at Arms
520 F.3d 490 (D.C. Circuit, 2008)
Baloch v. Kempthorne
550 F.3d 1191 (D.C. Circuit, 2008)
Taylor v. Solis
571 F.3d 1313 (D.C. Circuit, 2009)
Na'im v. Clinton
626 F. Supp. 2d 63 (District of Columbia, 2009)
Sharpe v. Bair
580 F. Supp. 2d 123 (District of Columbia, 2008)
Lester v. Natsios
290 F. Supp. 2d 11 (District of Columbia, 2003)

Cite This Page — Counsel Stack

Bluebook (online)
Jones v. Glaxosmithkline LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/jones-v-glaxosmithkline-llc-dcd-2010.